Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:13:28 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:DYAI from 2023-05-04 to 2024-05-03 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 16:30U:DYAINews ReleaseDyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
2024-03-28 16:00U:DYAINews ReleaseDyadic Reports 2023 Full Year Results and Recent Company Progress
2024-03-28 08:30U:DYAINews ReleaseDyadic Announces Change in Board and Management Leadership Roles
2024-03-27 08:30U:DYAINews ReleaseDyadic to Attend Industry Events in April
2024-03-26 08:30U:DYAINews ReleaseDyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
2024-03-21 08:30U:DYAINews ReleaseDyadic to Attend Future Food Tech Event March 21 - 22, 2024 in San Francisco, California
2024-03-14 16:30U:DYAINews ReleaseDyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
2024-03-11 09:57U:DYAINews ReleaseCORRECTION - Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
2024-03-11 08:30U:DYAINews ReleaseDyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
2024-03-01 08:30U:DYAINews ReleaseDyadic to Attend Industry Events in March
2024-02-28 08:30U:DYAINews ReleaseDyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform
2024-02-21 08:30U:DYAINews ReleaseDyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and ‚  Emerging Disease Solutions
2024-02-13 08:30U:DYAINews ReleaseDyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
2024-02-06 08:30U:DYAINews ReleaseDyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
2024-02-01 08:30U:DYAINews ReleaseDyadic to Attend BIO CEO & Investor Conference and European Industry Events
2024-01-22 08:02U:DYAINews ReleaseDyadic International, Inc Invites You to Join Us at The Microcap Conference
2024-01-02 08:30U:DYAINews ReleaseDyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
2023-11-30 08:30U:DYAINews ReleaseDyadic Attends Investor Events in December
2023-11-29 08:30U:DYAINews ReleaseDyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
2023-11-20 08:30U:DYAINews ReleaseDyadic ¢ € ™s C1 Platform to be Used to Produce Vaccines for ‚  Humans and Animals in Africa
2023-11-08 16:00U:DYAINews ReleaseDyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-10-30 08:30U:DYAINews ReleaseDyadic to Present at Industry Events in November
2023-10-25 16:30U:DYAINews ReleaseDyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
2023-10-09 08:30U:DYAINews ReleaseDyadic Appoints Doug Pace to Its Executive Leadership Team
2023-10-05 08:30U:DYAINews ReleaseDyadic ¢ € ™s C1 Platform Selected by the Vaccine and Immunotherapy Center ( ¢ € œVIC ¢ € ) at Massachusetts General Hospital as Part of VIC ¢ € ™s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production o
2023-09-29 08:30U:DYAINews ReleaseDyadic to Present at Industry and Investor Events in October
2023-09-26 08:30U:DYAINews ReleaseDyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
2023-09-19 08:00U:DYAINews ReleaseDyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus ¢ „ ¢
2023-09-12 16:30U:DYAINews ReleaseDyadic to Present at BioProcess International
2023-08-09 16:00U:DYAINews ReleaseDyadic Announces Second Quarter 2023 Financial Results and ‚  Highlights Recent Company Progress
2023-08-07 08:30U:DYAINews ReleaseDyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin
2023-07-26 16:30U:DYAINews ReleaseDyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
2023-07-24 08:30U:DYAINews ReleaseDyadic Provides Phase 1 Clinical Trial Update for its ‚  Recombinant Protein RBD Vaccine Candidate
2023-06-21 08:33U:DYAINews ReleaseDyadic Announced an MoU with Bangladesh ¢ € ™s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
2023-06-01 08:30U:DYAINews ReleaseDyadic to Participate at Upcoming Events in June
2023-05-10 16:00U:DYAINews ReleaseDyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
2023-05-10 08:30U:DYAINews ReleaseDyadic to Participate at Two Industry Events in May
2023-05-08 08:30U:DYAINews ReleaseDyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus ¢ „ ¢